Conditions: Nonalcoholic Steatohepatitis
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 289
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.

Detailed description:

Arms:
arm 1: CVC 150 mg tablet in Years 1 and 2. arm 2: Placebo-matching CVC tablet in Year 1 then CVC 150 mg tablet in Year 2. arm 3: Placebo-matching cenicriviroc (CVC) tablet in Years 1 and 2.

Interventions: intervention 1: Cenicriviroc intervention 2: Placebo
Intervention descriptions: intervention 1: CVC 150 mg, administered orally once daily and taken every morning with food. intervention 2: Placebo administered orally once daily and taken every morning with food.

Protocol document: